

# MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Implantable Cardioverter Defibrillator (ICD)
Policy Number	7.01.06
Category	Technology Assessment
Original Effective Date	09/16/99
Committee Approval Date	05/17/01, 06/20/02, 04/24/03, 10/15/03, 02/19/04, 03/17/05, 12/15/05, 09/21/06, 07/19/07, 08/21/08, 07/16/09, 07/15/10, 08/18/11, 08/16/12, 08/15/13, 08/21/14, 07/16/15, 03/17/16, 01/19/17, 02/15/18, 02/21/19, 04/16/20, 02/18/21, 08/19/21, 08/18/22, 08/17/23, 04/18/24
Current Effective Date	08/15/24
Deleted Date	N/A
Archived Date	N/A
Archive Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> <li>• Services are contract dependent; if a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</li> <li>• If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.</li> <li>• If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.</li> <li>• If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</li> <li>• If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.</li> </ul>

## POLICY STATEMENT

- I. Based upon our criteria and assessment of the peer-reviewed literature, use of an Implantable Cardiac Defibrillator (ICD) has been medically proven to be effective and, therefore, may be considered **medically appropriate** for the prevention of sudden cardiac death in patients who have **ANY** of the following:
  - A. Ischemic cardiomyopathy in individuals who have **ALL** of the following:
    1. Left Ventricular (LV) systolic dysfunction due to ischemic heart disease and **ALL** of the following:
      - a. LV ejection fraction less than or equal to 35% despite greater than or equal to three (3) months of optimal medical therapy; **and**
      - b. Symptomatic heart failure (New York Heart Association (NYHA) Functional Class II or Class III);
    - B. Ischemic cardiomyopathy in individuals with **ALL** of the following:
      1. LV systolic dysfunction due to ischemic heart disease and **ALL** of the following:
        - a. LVEF less than or equal to 30% despite greater than or equal to three (3) months of optimal medical therapy; **and**
        - b. NYHA functional Class I;
      - C. Ischemic cardiomyopathy in individuals who have LV systolic dysfunction due to ischemic heart disease and **ALL** of the following:
        1. LVEF of less than or equal to 40% despite greater than or equal to three (3) months of optimal medical therapy;
        2. Non-sustained ventricular tachycardia; **and**
        3. Inducible sustained monomorphic ventricular tachycardia (VT) at electrophysiological (EP) study;
      - D. Nonischemic dilated cardiomyopathy, who have **ALL** of the following:
        1. LVEF less than or equal to 35% despite greater than or equal to three (3) months of optimal medical therapy; **and**
        2. Symptomatic heart failure (NYHA Functional Class II or Class III CHF);

**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)**

**Policy Number: 7.01.06**

**Page: 2 of 12**

- E. Hypertrophic cardiomyopathy (HCM), who have **ONE OR MORE** of the following major risk factors for sudden cardiac death:
  - 1. Undiagnosed syncope;
  - 2. Family history of sudden death;
  - 3. Septal wall thickness of greater than or equal to 30 mm;
  - 4. Abnormal blood pressure response to exercise (systolic blood pressure (SBP) increase of less than 20mm/Hg with exercise or a drop in BP);
  - 5. Ventricular tachycardia sustained or nonsustained;
  - 6. LV apical aneurysm, independent of size; **and/or**
  - 7. LV ejection fraction less than 50%;
- F. Arrhythmogenic right ventricular cardiomyopathy (ARVC), with one or more risk factors for sudden cardiac death (unpredicted syncope, family history of sudden death, VT sustained or non-sustained, clinical signs of RV failure);
- G. In individuals with normal LV function (LVEF greater than 50%) with positive family history of sudden death;
- H. Long QT syndrome in the following settings:
  - 1. Syncope and/or VT while receiving beta-blockers or if beta-blockers are contraindicated;
  - 2. Asymptomatic with other risk factors for sudden cardiac death which include the following; QTc greater than 500msec or LQT 2 or 3, or family history of sudden death;
- I. Brugada syndrome with syncope or documented or inducible VT or VF;
- J. Familial cardiomyopathy individuals associated with sudden death;
- K. Nonsustained VT due to prior MI, LVEF less than 40%, and inducible VF or sustained VT observed and/or at electrophysiological study (EP) performed at least 96 hours after revascularization or MI;
- L. Sustained VT and normal or near normal ventricular function;
- M. Structural heart disease (e.g., prior MI, congenital heart disease, and/or ventricular dysfunction) with sustained VT (greater than 30 seconds);
- N. Structural heart disease (e.g., prior MI, congenital heart disease, and/or ventricular dysfunction and spontaneous, sustained VT (greater than 30 seconds) whether hemodynamically stable or non-stable;
- O. Syncope of undetermined origin and clinically relevant, hemodynamically significant, sustained VT or VF induced at EP study;
- P. Unexplained syncope, significant LV function (LVEF less than 50%) and structural heart disease, such as prior MI, congenital heart disease and/or ventricular dysfunction;
- Q. Catecholaminergic Polymorphic Ventricular Tachycardia who have syncope and/or documented sustained VT, while on beta-blocker therapy;
- R. Muscular dystrophy diagnosis, regardless of LVEF for **ANY** of the following:
  - 1. Emery-Dreifuss muscular dystrophy (EDMD);
  - 2. Limb-Girdle Type 1B muscular dystrophy (LGMD1B);
  - 3. Myotonic Dystrophy Type 1 with an indication for a permanent pacemaker; **or**
  - 4. Lamin A/C (LMNA) mutation (for patients who do not meet the above criteria of EDMD or LGMD1B) when there is documentation of **TWO OR MORE** of the following risk factors for sudden cardiac death:
    - a. Non-sustained ventricular tachycardia;
    - b. LVEF less than 45%;
    - c. Non-missense mutation (ins-del/truncating or mutations affecting splicing);
    - d. Male sex at birth;
- S. A documented episode of sustained ventricular tachyarrhythmia (either ventricular tachycardia (VT) or ventricular fibrillation (VF) lasting longer than 30 seconds), or cardiac arrest (either spontaneous or induced by an electrophysiology (EP) study) not associated with myocardial infarction (MI) whether hemodynamically stable or nonstable;
- T. Survivor of cardiac arrest due to VT or VF after evaluation has excluded any completely reversible causes;
- U. A documented cardiac sarcoid, or giant cell myocarditis or Chagas disease regardless of left ventricular ejection fraction (LVEF);
- V. Left ventricular (LV) non-compaction cardiomyopathy (left ventricular ejection fraction (LVEF) less than 50%);
- W. LV non-compaction:

## Medical Policy: **IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)**

Policy Number: **7.01.06**

Page: **3** of 12

1. In individuals with normal LV function (LVEF greater than 50%) with positive family history of sudden death;
  2. In individuals with impaired LV function (LVEF less than 50%) for primary prevention of sudden cardiac death due to malignant ventricular arrhythmias.
- II. Based upon our criteria and assessment of the peer-reviewed literature, the use of a subcutaneous ICD has been medically proven to be effective and, therefore, is considered medically appropriate for patients who have met the criteria for ICD implantation and who meet **ALL** of the following criteria:
- A. Have a contraindication to a transvenous ICD due to **ONE OR MORE** of the following:
    1. lack of adequate vascular access;
    2. compelling reason to preserve existing vascular;
    3. history of need for explanation of a transvenous ICD due to a complication, with ongoing need for ICD therapy;
  - B. have no indication for anti-bradycardia pacing;
  - C. do not have ventricular arrhythmias that are known or anticipated to respond to anti-tachycardia pacing.
- III. Based upon our criteria and assessment of the peer-reviewed literature, use of an ICD has not been medically proven to be effective and, therefore, is considered **investigational** in primary prevention for patients who have **ANY** of the following:
- A. had an acute MI (e.g., less than 40 days before ICD treatment);
  - B. had a cardiac revascularization procedure in the past three (3) months (coronary artery bypass graft or percutaneous transluminal coronary angioplasty) unless a separate indication for permanent pacemaker implantation exists;
  - C. NYHA Class IV heart failure, unless:
    1. Patient is eligible to receive a combination cardiac resynchronization therapy (CRT) ICD device;
    2. Patient is awaiting heart transplantation;
    3. A left ventricular assist device (LVAD) is being used as destination therapy;
  - D. an expected life expectancy of less than one year, even if meet ICD implantation criteria;
  - E. incessant VT or VF (e.g., hemodynamically stable VT or VF continuing for hours);
  - F. significant psychiatric illnesses that may be aggravated by device implantation or that may preclude systematic follow-up;
  - G. VF or VT is due to a reversible cause (i.e., severe electrolyte disturbance, drug induced torsades de pointes, acute re-perfused MI with preserved ejection fraction);
  - H. No structural heart disease and is a candidate for ablation.
- IV. Based upon our criteria and the lack of peer-reviewed literature, the use of a substernal implantable cardioverter-defibrillator systems has not been medically proven to be effective and, therefore, is considered **investigational**.

*Refer to Corporate Medical Policy #1.01.01 Transcutaneous and Percutaneous Nerve Stimulation as a Treatment for Pain and Other Conditions*

*Refer to Corporate Medical Policy #1.01.42 Home Automatic External Defibrillators (AEDs) and Wearable Cardioverter Defibrillators (WCDs)*

*Refer to Corporate Medical Policy #7.01.58 Permanent Pacemakers and Cardiac Resynchronization Therapy Devices*

*Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services*

### **POLICY GUIDELINES**

- I. When an ICD is to be implanted, there should first be a consultation with an electrophysiologist.
- II. Case reports have indicated that transcutaneous electrical nerve stimulators (TENS) have been known to interfere with ICDs and pacemakers.
- III. Optimal medical therapy should include a beta-blocker and **ONE** of the following:
  - A. ACE inhibitor;

## Medical Policy: **IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)**

**Policy Number: 7.01.06**

**Page: 4 of 12**

- B. Angiotensin II receptor blocker;
- C. Angiotensin receptor-neprilysin inhibitor.

### **DESCRIPTION**

An ICD is an electronic device designed to monitor a patient's heart rate, recognize VF or VT, and deliver an electronic shock to terminate these life-threatening arrhythmias. Indications for ICD implantation can be broadly subdivided into:

- I. Secondary prevention, e.g., for use in patients who have survived a prior sudden cardiac arrest or sustained VT; or
- II. Primary prevention or as a prophylactic, e.g., for use in patients with ischemic or nonischemic dilated cardiomyopathy or documented familial or inherited conditions, who are considered at high risk for sudden cardiac death, but who have not yet experienced life-threatening VT or VF.

While traditional ICDs have been used in the management of symptomatic and/or inducible VT and VF, technology has led to the development of a dual-chamber ICD that utilizes a sophisticated algorithm to detect and treat episodes of VT, VF, and, additionally, atrial fibrillation (AF). The prevention and treatment of AF focuses, first, on maintaining or restoring sinus rhythm (SR), and then on controlling rate and preventing thromboembolic events.

ICDs may be combined with biventricular pacing, to treat symptoms of advanced heart failure in certain patients who already need an ICD. These devices combine an ICD with CRT. The defibrillator component detects and treats life-threatening heart rhythms. The CRT component coordinates the beating of the left and right ventricles of the heart, so that they work together more effectively to pump blood throughout the body.

There are two different techniques for ICD electrode insertion: epicardial insertion, requiring a thoracotomy; or transvenous insertion, requiring a cutdown for direct vein insertion.

The subcutaneous ICD (subq-ICD) was developed to avoid some of the complications arising from using a traditional ICD. The subq-ICD consists of a dedicated external programmer, a subcutaneous pulse generator enclosed in a titanium case, and a single subcutaneous electrode containing both sensing and defibrillating components. The device uses proprietary algorithms to detect ventricular arrhythmias and can deliver a pulse of 80 J. The S-ICD system (Cameron Health, Inc.) received U.S. Food and Drug Administration (FDA) approval on September 28, 2012. The device was approved as defibrillation therapy for patients with life-threatening ventricular tachyarrhythmias who have not had symptomatic bradycardia, continual ventricular tachycardia, or spontaneous, frequently recurring VT that can be terminated with anti-tachycardia pacing.

Subq-ICDs are limited by the large size, inability to provide anti-tachycardia pacing, limited bradycardia pacing support, and a higher shock that must be delivered, compared to transvenous ICDs. The substernal or extravascular ICD has been proposed as an alternative to the subq-ICD. The lead is placed under the sternum in the substernal space (anterior mediastinum) for pacing and defibrillation. The placement allows for a lower energy to capture and defibrillate the heart, compared to a subcutaneous lead. There are clinical trials and studies underway to determine the usefulness of this approach for lead placement.

### **RATIONALE**

Professional Society Guidelines referenced for this policy:

<b>Professional Society</b>	<b>Title of Guideline</b>	<b>Year</b>
ACC/AHA/ACCP/HRS	Guidelines for the Diagnosis and Management of Atrial Fibrillation	2023
American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA)	Guideline for the Management of Heart Failure	2022

**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)****Policy Number: 7.01.06****Page: 5 of 12**

European Society of Cardiology (ESC)	Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death	2022
ESC	Guidelines for the diagnosis and treatment of acute and chronic heart failure	2021
AHA/ACC	Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy	2020
AHA/ACC/HRS	Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death	2017
ACC Foundation (ACCF)/AHA/HRS	Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities	2012

Prior to 2003, clinical evidence did not substantiate that implantation of a traditional ICD or a dual-chamber ICD improved net health outcomes in patients with non-coronary artery disease, congestive heart failure, cardiomyopathy, or acute MI. Recent clinical trials of prophylactic defibrillator implantation have presented varied results; the emerging evidence indicates that the prophylactic implantation of defibrillators reduces mortality among patients with an LV dysfunction, and that both ischemic and nonischemic patients achieved similar degrees of benefit from ICD therapy. Published evidence evaluating ICDs in patients with recent, acute MI does not establish the safety and efficacy of ICD therapy or demonstrate a reduction in mortality when ICD therapy is used in this population.

A subcutaneous ICD (S-ICD) has been developed as an alternative to venous pacing for patients with obstructed venous access and in whom continued venous access is difficult to maintain. The S-ICD is indicated for the treatment of life-threatening ventricular arrhythmias and contraindicated for patients with symptomatic bradycardia, incessant VT, and documented spontaneous, frequently recurring VT that is reliably terminated with anti-tachycardia pacing. The subcutaneous defibrillator may also be more appropriate in younger, more active children with limited venous access and congenital anomalies.

Medtronic PLC received FDA approval for their extravascular implantable cardioverter defibrillator (EV ICD) system, which consists of an ICD system with a substernal implantable defibrillator electrode to deliver defibrillation and anti-tachycardia pacing therapy. The EV ICD Pivotal study is a proactive, multicenter, single arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. It enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand. (Friedman, 2022) A Prospective, single group, nonrandomized, premarket global clinical study involving patients with a class I or IIa indication for an ICD, all of whom received an extravascular ICD system. A total of 356 patients were enrolled, 316 of whom had an implantation attempt. Among the 302 patients in whom ventricular arrhythmia could be induced and who completed the defibrillation testing protocol, the percentage of patients with successful defibrillation was 98.7%; 299 of 316 patients (94.6%) were discharged with a working ICD system. At 6 months, 25 major complications were observed, in 23 of 316 patients (7.3%). The success rate of antitachycardia pacing, as assessed with generalized estimating equations, was 50.8% (95% CI, 23.3 to 77.8). A total of 29 patients received 118 inappropriate shocks for 81 arrhythmic episodes. Eight systems were explanted without extravascular ICD replacement over the 10.6-month mean follow-up period. They found that extravascular ICDs were implanted safely and were able to detect and terminate induced ventricular arrhythmias at the time of implantation.

The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) showed noninferiority of subcutaneous implantable cardioverter defibrillator (S-ICD) compared with transvenous implantable cardioverter defibrillator (TV-ICD) regarding inappropriate shocks and complications. In contrast to TV-ICD, S-ICD cannot provide antitachycardia pacing for monomorphic ventricular tachycardia. This prespecified secondary analysis evaluates the appropriate therapy and whether antitachycardia pacing reduces the number of appropriate shocks. The PRAETORIAN trial was an international, investigator-initiated

**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)****Policy Number: 7.01.06****Page: 6 of 12**

randomized trial that included patients with an indication for implantable cardioverter defibrillator (ICD) therapy. Patients with previous ventricular tachycardia <170 bpm or refractory recurrent monomorphic ventricular tachycardia were excluded. In 39 centers, 849 patients were randomized to receive an S-ICD (n=426) or TV-ICD (n=423) and were followed for a median of 49.1 months. ICD programming was mandated by protocol. Appropriate ICD therapy was defined as therapy for ventricular arrhythmias. Arrhythmias were classified as discrete episodes and storm episodes ( $\geq 3$  episodes within 24 hours). In this trial, no difference was observed in shock efficacy of S-ICD compared with TV-ICD. Although patients in the S-ICD group were more likely to receive an ICD shock, the total number of appropriate shocks was not different between the 2 groups (Knops, 2022).

**CODES**

- Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/appropriate = (NMN).

**CPT Codes**

<b>Code</b>	<b>Description</b>
33215	Repositioning of previously implanted transvenous pacemaker or implantable defibrillator (right atrial or right ventricular) electrode
33216	Insertion of a single transvenous electrode, permanent pacemaker or implantable defibrillator
33217	Insertion of 2 transvenous electrodes, permanent pacemaker or implantable defibrillator
33218	Repair of single transvenous electrode, permanent pacemaker or implantable defibrillator
33220	Repair of two transvenous electrodes for permanent pacemaker or implantable defibrillator
33223	Relocation of skin pocket for implantable defibrillator
33230	Insertion of implantable defibrillator pulse generator only; with existing dual leads
33231	Insertion of implantable defibrillator pulse generator only; with existing multiple leads
33240	Insertion of implantable defibrillator pulse generator only; with existing single lead
33241	Removal of implantable defibrillator pulse generator only
33243	Removal of single or dual chamber implantable defibrillator electrode(s); by thoracotomy
33244	Removal of single or dual chamber implantable defibrillator electrode(s); by transvenous extraction
33249	Insertion or replacement of permanent implantable defibrillator system, with transvenous lead(s), single or dual chamber
33262	Removal of implantable defibrillator pulse generator with replacement of implantable defibrillator pulse generator; single lead system
33263	Removal of implantable defibrillator pulse generator with replacement of implantable defibrillator pulse generator; dual lead system

**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)****Policy Number: 7.01.06****Page: 7 of 12**

<b>Code</b>	<b>Description</b>
33264	Removal of implantable defibrillator pulse generator with replacement of implantable defibrillator pulse generator; multiple lead system
33270	Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters, when performed
33271	Insertion of subcutaneous implantable defibrillator electrode
33272	Removal of subcutaneous implantable defibrillator electrode
33273	Repositioning of previously implanted subcutaneous implantable defibrillator electrode
93260	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; implantable subcutaneous lead defibrillator system
93261	Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable subcutaneous lead defibrillator system
93282	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead transvenous implantable defibrillator system
93283	dual lead transvenous implantable defibrillator system
93295	Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional
93640	Electrophysiologic evaluation of single or dual chamber pacing cardioverter-defibrillator leads including defibrillation threshold evaluation (induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination) at time of initial implantation or replacement
93641	Electrophysiologic evaluation of single or dual chamber pacing cardioverter-defibrillator leads including defibrillation threshold evaluation (induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination) at time of initial implantation or replacement; with testing of single or dual chamber pacing cardioverter-defibrillator pulse generator
93642	Electrophysiologic evaluation of single or dual chamber transvenous pacing cardioverter-defibrillator leads (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)
93644	Electrophysiologic evaluation of subcutaneous implantable defibrillator (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)

**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)****Policy Number: 7.01.06****Page: 8 of 12**

<b>Code</b>	<b>Description</b>
0571T (E/I)	Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed
0572T (E/I)	Insertion of substernal implantable defibrillator electrode
0573T (E/I)	Removal of substernal implantable defibrillator electrode
0574T (E/I)	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode
0575T (E/I)	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional
0576T (E/I)	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter
0577T (E/I)	Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)
0578T (E/I)	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional (Report 0578T only once per 90 days)
0579T (E/I)	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results (Report 0579T only once per 90 days)
0580T (E/I)	Removal of substernal implantable defibrillator pulse generator only
0614T	Removal and replacement of substernal implantable defibrillator pulse generator

*Copyright © 2024 American Medical Association, Chicago, IL***HCPCS Codes**

<b>Code</b>	<b>Description</b>
C1721	Cardioverter-defibrillator, dual chamber (implantable)
C1722	Cardioverter-defibrillator, single chamber (implantable)
C1882	Cardioverter-defibrillator, other than single or dual chamber (implantable)
C1895	Lead, cardioverter-defibrillator, endocardial dual coil (implantable)



**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)****Policy Number: 7.01.06****Page: 9 of 12**

<b>Code</b>	<b>Description</b>
C1896	Lead, cardioverter-defibrillator, other than endocardial single or dual coil (implantable)
C1899	Lead, pacemaker / cardioverter-defibrillator, combination (implantable)

**ICD10 Codes**

<b>Code</b>	<b>Description</b>
I25.10-I25.119	Atherosclerotic heart disease of native coronary artery (code range)
I25.3-I25.42	Aneurysm of heart (code range)
I25.5-I25.6	Myocardial ischemia (code range)
I25.700-I25.739	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris (code range)
I25.750-I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart (code range)
I25.790-I25.799	Atherosclerosis of other coronary artery bypass graft(s) (code range)
I25.810	Atherosclerosis of other coronary vessels without angina pectoris
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris
I25.82	Chronic total occlusion of coronary artery
I25.83-I25.84	Coronary atherosclerosis due to lipid rich plaque or calcified coronary lesion (code range)
I25.89	Other forms of chronic ischemic heart disease
I25.9	Chronic ischemic heart disease, unspecified
I42.0-I42.9	Cardiomyopathy (code range)
I46.2-I46.9	Cardiac arrest (code range)
I47.0	Re-entry ventricular arrhythmia
I47.2	Ventricular tachycardia
I48.0-I48.91	Atrial fibrillation and flutter (code range)
I49.01-I49.02	Ventricular fibrillation or ventricular flutter (code range)
I49.9	Cardiac arrhythmia, unspecified
I50.1	Left ventricular failure, unspecified
I50.20-I50.23	Systolic (congestive) heart failure (code range)
I50.30-I50.33	Diastolic (congestive) heart failure (code range)
I50.40-I50.43	Combined systolic (congestive) and diastolic (congestive) heart failure (code range)
I50.9	Heart failure, unspecified

## Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)

Policy Number: 7.01.06

Page: 10 of 12

### REFERENCES

- \*Al-Khatib SM, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018 Oct;15(10):e190-e252.
- \*Al-Khatib SM, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005 Jun;149(6):1020-34.
- \*Almendral J and Josephson ME. All patients with hemodynamically tolerated postinfarction ventricular tachycardia do not require an implantable cardioverter-defibrillator. Circulation 2007 Sep 4;116(10):1204-12.
- \*Barsheshet A, et al. Applicability of a risk score for prediction of the long-term (8 year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol 2012 Jun 5;59(23):2075-9.
- \*Begley DA, et al Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003 Sep;26(9):1887-96.
- \*Berul CI, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008 Apr 29;51(17):1685-91.
- Boersma LV, et al. Therapy from a Substernal Lead: The ASD2 Study. J Am Coll Cardiol: Clin EP 2019;5:186-96.
- Broers ER, et al. Personality traits, ventricular tachyarrhythmias, and mortality in patients with an implantable cardioverter defibrillator: 6 years follow-up of the WEBCARE cohort. General Hospital Psychiatry 2020 Jan; 62:56-62.
- \*Bunch TJ, et al. Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators. Circulation 2007 May 8;115(18):2451-7.
- \*Buxton AE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 2007 Sep 18;50(12):1150-7.
- \*Chan PS, et al. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. Arch Intern Med 2006 Nov 13;166(20):2228-33.
- \*Desai AD, et al. Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2006 May;17(5):486-90.
- Fong KY, et al. Subcutaneous versus transvenous implantable defibrillator therapy: a systematic review and meta-analysis of randomized trials and propensity score-matched studies. Journal of the American Heart Association 2022 Jun;11(11):1-18.
- Friedman P, et al. Extravascular ICD Pivotal Study Investigators. Efficacy and Safety of an Extravascular Implantable Cardioverter-Defibrillator. N Engl J Med 2022 Oct 6;387(14):1292-1302.
- \*Gregoratos G, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices; a report of the American College of Cardiology/American Heart Association task Force on Practice Guidelines. [<https://sciencedirect.com/science/article/pii/S0735109702025287?via%3Dihub>] accessed 01/11/24.
- \*Heidenrich PA, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 2022 May;145(18):e895-e1032.
- Hernandez-Ojeda J, et al. The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. JAHJ 2019;10.016.
- Hess PL, et al. Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. Clinical Cardiology 2019 Nov;1-9.

**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)**

**Policy Number: 7.01.06**

**Page: 11 of 12**

Ip, James E. Managing elevated subcutaneous implantable cardioverter-Defibrillator defibrillation thresholds: The importance of implantation technique. Journal of Cardiovascular Electrophysiology 2021 Jan.

\*Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. circulation 2024 Jan 2;149(1):e1-e156.

Kawamura I, et al. Patient characteristics and in-hospital complications of subcutaneous implantable cardioverter-defibrillator for Brugada syndrome in Japan. Journal of Arrhythmia 2019 Aug;35:842–847.

Kleeman T, et al. Long-term performance and lead failure analysis of the Durata defibrillation lead compared to its previous model, the recalled Riata defibrillation lead. Journal of Cardiovasc Electrophysiol 2019 Jul;30:2012-2019.

Knops RE, et al. Efficacy and safety of appropriate shocks and antitachycardia pacing in transvenous and subcutaneous implantable defibrillators: analysis of all appropriate therapy in the praetorian trial. Circ 2022 Feb;145(5):321-329.

\*Maron BJ, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003 Nov 5;42(9):1687-713.

\*Maron BJ, et al Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circ 2003 Jun 17;107(23):2872-5.

\*Maisel WH. Pacemaker and ICD generator reliability: meta-analysis of device registries. JAMA 2006 Apr 26;295(16):1929-34.

McDonagh TA, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022 Jan;24(1):4-131.

\*Moss AJ. What we have learned from the family of multicenter automatic defibrillator implantation trials. Circ J 2010 Jun;74:1038-41.

\*Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEJM 2002 Mar 21;346(12):877-83.

\*Ommen SR, et al. AHA/ACC 2020 guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circ 2020 Dec;142(25):e558-e631.

\*Reichlin Y, et al. Characterization and financial impact of implantable cardioverter-defibrillator patients without interventions 5 years after implantation. QJM 2011 Oct;104(10):849-57.

Ricciardi D, et al. Clinical impact of defibrillation testing in a real-world S-ICD population: Data from the ELISIR registry. J Cardiovasc Electrophysiol 2020;1-9.

Rordorf R, et al. Subcutaneous versus transvenous implantable defibrillator: an updated meta-analysis. Heart Rhythm Society 2021 Mar;18(3):382-391.

\*Sacher F, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circ 2006 Nov 28;114(22):2317-24.

\*Saxon LA, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Circ 2006 Dec 19;114(25):2766-72.

\*Saxon LA, et al. Results of the multicenter RENEWAL 3 AVT clinical study of cardiac resynchronization defibrillator therapy in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2006 May;17(5):520-5.

**Medical Policy: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)**

**Policy Number: 7.01.06**

**Page: 12 of 12**

Sirico G, et al. Myotonic dystrophy type 1 and high ventricular vulnerability at the electrophysiological evaluation: ICD yes or not? Acta Myol 2020 Mar 1;39(1):32-35.

\*Tracy CM, et al. 2012 ACCF/AHA/HRS Focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2012 Dec;144(6):e127-45.

\*Zareba W, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003 Apr;14(4):337-41.

Zeitler EP, et al. Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. Heart Rhythm 2020 Mar;17(3):447-454.

Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022 Oct 21;43(40):3997-4126.

\*Key Article

**KEY WORDS**

AICD, Automatic implantable cardioverter defibrillator, Cardiac resynchronization, ICD.

**CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently a National Coverage Determination (NCD) for Implantable Automatic Defibrillators (20.4). Please refer to the following NCD website for Medicare Members: [<https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=110&ncdver=4&bc=AAAAgAAAAAA&>] accessed 01/11/24.